Dosage Form Design (IMP) GTU
Ch-1 Controlled & Sustained release dosage form
Q.1) Describe in detail physicochemical factors affecting design of oral sustained release dosage forms.
Q.2) Discuss the merits and demerits of controlled release dosage forms.
Q.3) Write in brief the estimation of loading and maintenance dose for a controlled release formulations.
Q.4) Discuss the ideal requirements for sustained release formulations.
Discuss selecton criteria of polymers used in novel parenteral formulations with example.
Q.5) Describe bioerodible and combination of diffusion dissolution system with examples.
Q.6) Enumerate the evaluation parameters for parenteral controlled
Q.7) Enlist various parenteral drug delivery system and explain any one in detail.
Q.8) Explain importance of tortuosity and porosity in dissolution.
Q.9) Explain lag time & burst effect in controlled drug delivery system with diagram.
Q.10) Write a note on reservoir type of controlled drug delivery system.
Q.11) Give example of hydrophobic type of matrix system and explain mechanism of drug release from it.
Q.12) Mention the parameters and methods used for evaluation of microspheres.
Q.13) Write in detail formulation design of transdermal drug delivery system.
Q.14) Classify the polymers used for preparation of matrix tablets. Give two names of each class.
Q.15) Discuss the properties of drug that can be enhanced by drug carrier delivery system for drug-targeting.
Q.16) What are the properties required for the drug to be a candidate for TDDS? Write evaluation method for adhesive properties of TDDS.
Q.17) Describe in detail preparation of HBS for gastric retention of oral dosage forms. What is the method of evaluation of such dosage forms for gastric retention time?
Q.18) Discuss in detail the evaluation parameters for transdermal patches.
Q.19) Explain Ocusert® and Lacrisert®.
Q.20) Difference between liposomes and niosomes.
Q.21) Write a note on osmotic ocular inserts. Mention the components of each part.
Q.22) Discuss the formulations development of osmotic tablets with example.
Q.23) Describe formulation and evaluation of liposomes.
Q.24) Enumerate various approaches employed for preparation of targeted drug delivery systems. Discuss any one in detail along with examples.
Q.25) Explain top down production of nanoparticles along with examples.
Q.26) Justify the rationale for gastro-retentive drug delivery systems and explain low density approach & expandable approach.
Q.27) Enumerate various methods for preparations of liposomes. Explain any one of them in detail.
Q.28) Enlist various approaches for colon targeted delivery of intact molecule. Explain any one of them with example.
Q.29) Comment:- a) Niosomes are more stable than Liposomes
b) Microspheres exhibit all or none phenomena.
Q.30) Enlist various methods of preparations of microspheres and explain double emulsion method in detail. Also explain its evaluation.
Q.31) Enlist different types of hydrogels and explain in-situ gel in detail.
Q.32) Elaborate effervescent system in GRDDS.
Q.33) Describe floating drug delivery system.
Q.34) Short note on “Pulsincap” with appropriate figure.
Q.35) Enlist different pharmacokinetic models. What is compartment model? Mention advantages and disadvantages of the same.
Q.36) Discuss Michaeles Menten equation for nonlinear pharmacokinetics.
Q.37) Discuss Wagner-Nelson and Loo-Riegelman method.
Q.38) Discuss various causes for non linearity of drugs.
Q.39) Explain and justify the importance of apparent volume of distribution.
Q.40) What are pharmacokinetic models? Explain in detail one compartment model.
Q.41) Explain influence of extraction ratio in hepatic clearance.
Q.42) Explain catenary and mammillary compartments models in detail.
Q.43) Give advantages and disadvantages of compartment modeling.
Q.44) Define Cmax, Volume of distribution, compartment model, Total clearance.
Q.45) Derive equations for first and zero order kinetics.
Q.46) Write merits of non compartmental analysis. Explain AUC & AUMC plots.
Ch-4 Clinical Pharmacokinetics
Q.47) Define Clinical Pharmacokinetics. Write a brief note on pharmacokinetic drug interactions.
Q.48) Define and explain Scope of Clinical Pharmacokinetics. Discuss the importance of dosage regimen for patients with renal failure.
Q.49) Explain appropriately with equations if necessary, dosage adjustment in patients with renal failure & hepatic failure.
Q.50) Explain methods for the calculations of creatinine from serum creatinine concentration.
Q.51) Explain “Drug interaction”. Discuss ADME drug interaction with suitable example.